By suppressing the activity of various receptor tyrosine kinase and VEGF/Raf/MER/ERK-mediated multiple signaling pathways, sorafenib can inhibit tumor cell proliferation and angiogenesis in vivo [37]. This evidence concerns the gene NTRK1 and neoplasm.